Evotec

Global Central Nervous System Drugs Market Report (2021 to 2030) - COVID-19 Impact and Recovery - ResearchAndMarkets.com

Thursday, May 6, 2021 - 3:35pm

Asia Pacific was the second largest region accounting for 22% of the global central nervous system drugs market.

Key Points: 
  • Asia Pacific was the second largest region accounting for 22% of the global central nervous system drugs market.
  • Africa was the smallest region in the global central nervous system drugs market.\nMany central nervous system drug manufacturers are collaborating with other manufacturers in the industry to share technical knowledge and improve product quality.
  • In October 2016, UCB Pharmaceuticals signed a partnership agreement with Evotec for the research and development of drugs for nervous disorders such as epilepsy, Parkinson's and Alzheimer's diseases.\nThe central nervous system drugs market was mainly driven by rapid growth in emerging markets in the historic period.
  • Thus, strong economic growth boosted the demand for central nervous system drugs and this drove the market during the historic period.\n"

DGAP-News: Evotec launches 'beLAB1407' to accelerate translational research from the UK's academic life science ecosystem in collaboration with Bristol Myers Squibb

Thursday, May 6, 2021 - 7:00am

"\nDr Rupert Vessey, Executive Vice President and President, Research and Early Development at Bristol Myers Squibb, commented: "This collaboration builds on our important connection to leading European universities.

Key Points: 
  • "\nDr Rupert Vessey, Executive Vice President and President, Research and Early Development at Bristol Myers Squibb, commented: "This collaboration builds on our important connection to leading European universities.
  • With beLAB1407, we are supporting U.K.-based universities that are exploring many interesting lines of scientific research and discovery.
  • That research combined with Evotec\'s proprietary data platforms has the potential to identify new and novel therapies for areas of unmet medical need.
  • "\nDr George Baxter, Chief Executive of Edinburgh Innovations, said: "This innovative collaboration represents the best of academic and industry collaboration.

DGAP-News: Evotec SE to announce results for the first quarter 2021 on 11 May 2021

Tuesday, May 4, 2021 - 11:28am

We operate worldwide and our more than 3,700 employees provide the highest quality stand-alone and integrated drug discovery and development solutions.

Key Points: 
  • We operate worldwide and our more than 3,700 employees provide the highest quality stand-alone and integrated drug discovery and development solutions.
  • We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute).
  • Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others.
  • The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release.

DGAP-News: Evotec and the GCKD study enter into strategic collaboration to build a unique molecular patient database

Tuesday, May 4, 2021 - 7:01am

Under the agreement, the research team will make use of Evotec\'s proprietary EVOpanOmics and EVOpanHunter platforms to facilitate deep molecular profiling of patient samples.

Key Points: 
  • Under the agreement, the research team will make use of Evotec\'s proprietary EVOpanOmics and EVOpanHunter platforms to facilitate deep molecular profiling of patient samples.
  • The Evotec platforms combine enhanced throughput proteomics, high-throughput transcriptomics and integrated data analysis.\nInitiated in 2009, GCKD was designed to be the world\'s largest cohort study on chronic kidney disease.
  • This collaboration is a major step forward towards this goal and we are very excited about the opportunity to work with this unique network.
  • The GCKD cohort not only complements and expands our already leading kidney disease data base with well-documented long-term survey of CKD patients and corresponding patient samples.

Proactive news headlines including Chase Mining Corporation, Red River Resources, Aurumin and Kazia Therapeutics

Monday, April 26, 2021 - 7:14am

Click here\nRed River Resources Ltd (ASX:RVR) has received encouraging initial results from its first-pass reverse circulation (RC) drilling program at the New Homestead and Don gold prospects, part of its Thalanga Operations in northern Queensland.

Key Points: 
  • Click here\nRed River Resources Ltd (ASX:RVR) has received encouraging initial results from its first-pass reverse circulation (RC) drilling program at the New Homestead and Don gold prospects, part of its Thalanga Operations in northern Queensland.
  • Click here\nAurumin Ltd (ASX:AUN) has started reverse circulation (RC) drilling at its 100%-owned Mt Palmer Project, about 40 kilometres east-southeast of Southern Cross in Western Australia\xe2\x80\x99s Goldfields.
  • Click here\nKazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) recently announced an agreement with Evotec SE (FRA:EVT) to in-license the global rights to EVT801, a novel inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3).
  • Click here\nMatador Mining Ltd (ASX:MZZ) (FRA:MA3) is seeking to broaden its investor base by listing on multiple international platforms to complement its Australian Securities Exchange listing.

DGAP-News: Bristol Myers Squibb exercises option to extend targeted protein degradation partnership with Evotec

Monday, April 26, 2021 - 7:01am

b'The issuer is solely responsible for the content of this announcement.\nEvotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that Bristol Myers Squibb has decided to exercise their option to extend its partnership with Evotec in the field of targeted protein degradation.

Key Points: 
  • b'The issuer is solely responsible for the content of this announcement.\nEvotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that Bristol Myers Squibb has decided to exercise their option to extend its partnership with Evotec in the field of targeted protein degradation.
  • The success of our collaboration with Bristol Myers Squibb to date has led to Bristol Myers Squibb\'s decision to expand and extend this collaboration.
  • Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others.
  • The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release.

Proactive news headlines including Queensland Pacific Metals, Moho Resources, Kazia Therapeutics and Perseus Mining

Tuesday, April 20, 2021 - 7:13am

Click here\nMoho Resources Ltd's (ASX:MOH) is encouraged by results from maiden RC drilling at Crossroads gold prospect of the Burracoppin Project in the WA wheatbelt that show extensive gold mineralisation.

Key Points: 
  • Click here\nMoho Resources Ltd's (ASX:MOH) is encouraged by results from maiden RC drilling at Crossroads gold prospect of the Burracoppin Project in the WA wheatbelt that show extensive gold mineralisation.
  • Click here\nKazia Therapeutics Ltd (ASX:KZA) (FRA:NV9) (NASDAQ:KZIA) has entered into a worldwide exclusive licensing agreement as well as a master services agreement with Evotec SE (FRA:EVT) \xe2\x80\x93 a leading European drug discovery and development company.
  • Click here\nCarnavale Resources Ltd (ASX:CAV) (FRA:YBB) has been granted ministerial consent for the transfer of 100% of the Barracuda Platinum-Palladium-Nickel-Copper Project near Mt Magnet in Western Australia to the company.
  • Click here\nKingwest Resources Ltd (ASX:KWR) is progressing towards a pre-feasibility study and near-term production at the Menzies Gold Project (MGP) in Western Australia.

Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE

Monday, April 19, 2021 - 11:11am

Evotec have done first-class work in the early development of EVT801, and the preclinical data package is exceptionally strong.

Key Points: 
  • Evotec have done first-class work in the early development of EVT801, and the preclinical data package is exceptionally strong.
  • We intend to fast track a phase I clinical trial of the drug, which we expect to commence in CY2021.
  • "\nHe added, "As we have built Kazia over the past five years, our strategy has been to assemble a portfolio of world-class development candidates through in-licensing.
  • "\nEvotec CEO, Dr Werner Lanthaler, commented, "we are very pleased to partner with Kazia for this promising asset, for which we have high hopes.

Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE

Monday, April 19, 2021 - 10:36am

Evotec have done first-class work in the early development of EVT801, and the preclinical data package is exceptionally strong.

Key Points: 
  • Evotec have done first-class work in the early development of EVT801, and the preclinical data package is exceptionally strong.
  • We intend to fast track a phase I clinical trial of the drug, which we expect to commence in CY2021.
  • "\nHe added, "As we have built Kazia over the past five years, our strategy has been to assemble a portfolio of world-class development candidates through in-licensing.
  • "\nEvotec CEO, Dr Werner Lanthaler, commented, "we are very pleased to partner with Kazia for this promising asset, for which we have high hopes.

DGAP-News: Evotec and Exscientia announce start of human clinical trials of novel immuno-oncology drug

Friday, April 9, 2021 - 7:00am

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the most advanced asset arising from their joint venture with Exscientia has entered human clinical trials.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the most advanced asset arising from their joint venture with Exscientia has entered human clinical trials.
  • Dr Craig Johnstone, Chief Operating Officer of Evotec, commented: "We highly value our ongoing partnership with Exscientia, which has been highly collaborative and productive in every respect.
  • We are therefore delighted to announce the start of clinical development of our co-owned A2a antagonist with Exscientia in the hope that the fruits of our collaboration can bring potential benefits to patients in the future."
  • Exscientia will lead further clinical development of the molecule and Evotec will retain co-ownership rights throughout clinical development.